Estrogen receptor activation function 2 (AF-2) is essential for hormone-dependent transactivation and cell transformation induced by a v-Jun DNA binding domain-estrogen receptor chimera

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1628, Issue 3, 2003, Pages 147-155

  Dunn, Catherine A ^a,c   Clark, William ^a   Black, Elizabeth J ^a   Gillespie, David A F ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

AF 2 domain; Cell transformation; Estrogen receptor; Transcription; v Jun

Indexed keywords

ACTIVATION FUNCTION 2; ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN; PROTEIN V JUN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CHIMERA; CONTROLLED STUDY; DNA BINDING; DNA TRANSCRIPTION; HORMONAL REGULATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSACTIVATION;

EID: 0043157871     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(03)00136-2     Document Type: Article

References (32)

1. Maki Y., Bos T.J., Davis C., Starbuck M., Vogt P.K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl. Acad. Sci. U. S. A. 84:1987;2848-2852.
2. Bos T.J., Monteclaro F.S., Mitsunobu F., Ball A.R. Jr., Chang C.H., Nishimura T., Vogt P.K. Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev. 4:1990;1677-1687.
3. Wong W.Y., Havarstein L.S., Morgan I.M., Vogt P.K. c-Jun causes focus formation and anchorage-independent growth in culture but is non-tumorigenic. Oncogene. 7:1992;2077-2080.
4. Clark W., Gillespie D.A. Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors. Cell Growth Differ. 8:1997;371-380.
5. Clark W., Black E.J., MacLaren A., Kruse U., LaThangue N., Vogt P.K., Gillespie D.A. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity. Mol. Cell. Biol. 20:2000;2529-2542.
6. Hartl M., Bister K. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation. Oncogene. 17:1998;2901-2913.
7. Hussain S., Kilbey A., Gillespie D.A. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter. Cell Growth Differ. 9:1998;677-686.
8. Fu S., Bottoli I., Goller M., Vogt P.K. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5716-5721.
9. Hartl M., Reiter F., Bader A.G., Castellazzi M., Bister K. JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13601-13606.
10. Bader A.G., Schneider M.L., Bister K., Hartl M. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene. 20:2001;7524-7535.
11. Cohen S.B., Waha A., Gelman I.H., Vogt P.K. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10 T1/2 murine fibroblasts. Oncogene. 20:2001;141-146.
12. Vial E., Castellazzi M. Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo. Oncogene. 19:2000;1772-1782.
13. Vogt P.K. Jun, the oncoprotein. Oncogene. 20:2001;2365-2377.
14. Kruse U., Iacovoni J.S., Goller M.E., Vogt P.K. Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12396-12400.
15. Picard D., Salser S.J., Yamamoto K.R. A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor. Cell. 54:1988;1073-1080.
16. Webster N.J., Green S., Jin J.R., Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell. 54:1988;199-207.
17. Fialka I., Schwarz H., Reichmann E., Oft M., Busslinger M., Beug H. The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions. J. Cell Biol. 132:1996;1115-1132.
18. Francis M.K., Phinney D.G., Ryder K. Analysis of the hormone-dependent regulation of a JunD-estrogen receptor chimera. J. Biol. Chem. 270:1995;11502-11513.
19. Kim S., Brown P.H., Birrer M.J. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 12:1996;1043-1053.
20. Morgan I.M., Ransone L.J., Bos T.J., Verma I.M., Vogt P.K. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos. Oncogene. 7:1992;1119-1125.
21. Kilbey A., Black E.J., Unlu M., Gillespie D.A. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction. Oncogene. 12:1996;2409-2418.
22. May G.H., Funk M., Black E.J., Clark W., Hussain S., Woodgett J.R., Gillespie D.A. An oncogenic mutation uncouples the v-Jun oncoprotein from positive regulation by the SAPK/JNK pathway in vivo. Curr. Biol. 8:1998;117-120.
23. Black E.J., Clark W., Gillespie D.A. Transient deactivation of ERK signalling is sufficient for stable entry into G0 in primary avian fibroblasts. Curr. Biol. 10:2000;1119-1122.
24. Franza B.R. Jr., Josephs S.F., Gilman M.Z., Ryan W., Clarkson B. Characterization of cellular proteins recognizing the HIV enhancer using a microscale DNA-affinity precipitation assay. Nature. 330:1987;391-395.
25. Danielian P.S., White R., Lees J.A., Parker M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11:1992;1025-1033.
26. Stafford G.A., Morse R.H. Mutations in the AF-2/hormone-binding domain of the chimeric activator GAL4.estrogen receptor.VP16 inhibit hormone-dependent transcriptional activation and chromatin remodeling in yeast. J. Biol. Chem. 273:1998;34240-34246.
27. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 375:1995;377-382.
28. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
29. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
30. Feng W., Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
31. Henttu P.M., Kalkhoven E., Parker M.G. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 17:1997;1832-1839.
32. Bannister A.J., Oehler T., Wilhelm D., Angel P., Kouzarides T. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene. 11:1995;2509-2514.